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ABSTRACT 
Objective: This study was designed to develop and validate a simple, rapid, and economical UV-spectrophotometric method using a solubilising agent for the estimation of Riluzole. 
Methods: In this study, a solution of 2% SLS (Sodium Lauryl Sulphate) in PH 9.2 buffers was employed as the solubilising agent to solubilise a poorly water-soluble drug, Riluzole. In the UV-spectrophotometric method, Riluzole was estimated at 225 nm using solubilising agent. 
Results: Solubilising agent used did not interfere in spectrophotometric analysis of Riluzole. Riluzole followed linearity in the concentration range of 1-5 μg/ml with a coefficient correlation of 0.998. 
Conclusion: The developed method has shown to be linear (r2 = 0.9984), precise (%R. S. D of 0.87 and 0.84 at intra and inter day respectively), 
accurate (recovery of 100.37%) with limit of detection (0.54 µg/ ml) and limit of quantification of 1.64µg/ ml as per ICH guidelines.  
Keywords: Riluzole, UVspectroscopyy, SLS (Sodium Lauryl Sulphate), PH 9.2 buffer. 
 
INTRODUCTION Riluzole is the only FDA-approved drug currently used for the treatment of amyotrophic lateral sclerosis (ALS), a progressive, fatal, neurodegenerative disorder caused by deterioration of voluntary muscle controlling motor neurons leading to paralysis state and long term disability [1]. Three mechanisms are proposed for action of RIL: inhibition of excitatory amino acid release, inhibition of events following stimulation of excitatory amino acid receptors and stabilization of the inactivated state of voltage-dependent sodium channels. RIL offers neuro-protective action and prolongs the life of ALS patient. In vivo, it has neuroprotective, anticonvulsant, and sedative properties [2]. 
RIL is chemically 6-(trifluoromethoxy) benzothiazol-2-amine. The structure of Riluzole is presented in Fig 1. It is very slightly soluble in water and is weakly basic (pKa3.5) in nature. Post oral administration, it is rapidly absorbed from gastro–intestinal tract 
and has an absolute bioavailability of about 60% in humans. It is extensively metabolized, primarily by cytochrome P450 1A2[3]. 
 
Fig. 1: Structure of Riluzole Literature survey revealed that Riluzole was estimated analytically 
using different analytical techniques like UV spectroscopy [5], 
HPLC[5][7], HPTLC[7] and Stability indicating methods[5][6]. Most of the UV spectrophotometric methods developed employed organic solvents to solubilise the drug[8].Only one solubility enhancement method was reported for the estimation of Riluzole by using UV spectrophotometry, which used 5M sodium benzoate as a hydrotropic solubilising agent[4]. Drawbacks of organic solvents include their higher cost, toxicity, and pollution. In addition, Riluzole is poorly soluble in water. Therefore, the solubility enhancement 
technique may be a suitable alternative to exclude the use of organic 
solvents. Special systems are required to solubilise poorly water-soluble drugs. Out of many solubilising agents tried, there was a miraculous synergistic effect on enhancement in solubility of a poorly water-soluble drug by mixing 2% SLS in PH 9.2 buffers.  The objective of the present investigation is to develop simple, precise, accurate and economical UV-spectrophotometric method for 
the determination of Riluzole using suitable solubilising agent. The developed method was validated as per the ICH guidelines. 
MATERIALS AND METHODS 
Chemicals Riluzole hydrochloride, PH 9.2 buffer capsules were purchased from Merck speciality pvt. Ltd. SLS was purchased from Merck speciality pvt. Ltd. 
Instrumentation A UV-visible spectrophotometer systronics pc based double beam 
spectrophotometer 2202 employed for all spectroscopic measurements, using a pair of 1 mm matched quartz cells. 
Selection of solvent 2% SLS (Sodium Lauryl Sulphate) in PH 9.2 buffer solution was selected as a solvent for developing spectral characteristics of a drug. The selection was made after assessing the solubility in different hydrotropic solubilising agents. 
Preparation of stock standard solutions 
Stock standard solutions of Riluzole were prepared by dissolving 10 
mg in a 100 mL volumetric flask containing 25 ml of 2% SLS (Sodium Lauryl Sulphate) in PH 9.2 buffer solution, the solution was heated slightly on a water bath to ensure complete dissolving and the volume was made up to the mark with the same to obtain the 
concentration 100 μg/ml. After appropriate dilutions, 10 μg/ml Riluzole was scanned in the UV-region, i. e. 200–400 nm. Riluzole showed λmax of 225 nm in 2% SLS (Sodium Lauryl Sulphate) in PH 9.2 buffer solution. 
Validation of the developed method [9] 
Specificity and selectivity  The specificity of Riluzole was estimated by checking the interference and interaction of SLS with drug. 
Accuracy  As a part of determining accuracy of the proposed method, different 
levels of drug concentrations (50%, 100%, and 150%) were prepared from independent stock solution and analysed. Accuracy was assessed as the percentage recovery and mean percentage recovery. 
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Precision  
Repeatability was determined by using a drug concentration of 4 
µg/ml prepared from independent stock solution and analysed. Inter-day and Intra-day variation was taken to determine the intermediate precision of the proposed method. The relative standard deviation (% RSD) of the predicted concentrations from 
the regression equation was taken as precision. 
Linearity  To establish linearity of the proposed method, six separate series of solution of the drug (1-5 µg/ml using 2% SLS in PH 9.2 buffer solution) were prepared and analysed. Least square regression analysis was done for the obtained data.  
Detection limit (LOD) and Quantitation limit (LOQ)  The LOD and LOQ of Riluzole by the proposed method were determined using calibration standard. LOD and LOQ were 
calculated as 3.3σ/S and 10σ/S, respectively, where S is the slope of 
the calibration curve and σ is the standard deviation of y intercept of the regression equation. 
Robustness  Robustness of the proposed method was determined by changing the wavelength of estimation by ±2 nm. Mean % recovery was determined. 
RESULTS AND DISCUSSION Absorption spectrum of Riluzole was estimated and λmax was found to be 225 nm. Calibration curve was plotted and the linear 
regression equation obtained was y = 0.1047x + 0.004 with regression co-efficient 0.9984. The method was validated in 
accordance with the current ICH guidelines. The study of Beer’s- 
Lambert’s law was checked by preparing standard solution at six different concentrations and the linearity of the calibration graphs and conformity of the UV-VIS measurement of the proposed 
methods to Beer’s law were proven by the values of the correlation co- efficient of the absorptivity study.  
 
Fig. 2: Calibration/Standard curve for Riluzole 
 
Table 1: Accuracy of Riluzole 
Drug Theoretical content % recovery Mean recovery RIL 50%(1µg/ml) 1 102.5 100.66% 2 101.0 
3 98.5 RIL 100%(3µg/ml) 1 99.25 100.45% 2 100.7 
3 101.4 RIL 150%(5µg/ml) 1 100 100.02% 2 100.9 
3 99.16 Mean = 100.37% 
 The linear range of concentration for the analysis of riluzole was found to be 1-5 µg/ml for UV-spectrophotometric method and calibration curve was represented in figure-2. Mean % recoveries of riluzole by UV-VIS method were found to be 100.37% which was tabulated in table-1. The reproducibility and repeatability of the 
developed method were established by the study of precision. The % RSD was found to be 0.87 and 0.84 at intra and inter day respectively for UV-VIS spectroscopic method. Robustness of the proposed method was carried out and the results did not show any considerable statistical difference suggesting that the method 
developed was robust. Brief information regarding the results of the proposed method was presented in table– 2. 
[ 
Table 2: Results of the developed method 
Parameter Result 
λmax 225 nm 
Beer’s law limits (µg/ml) 1 – 5  Molar absorptivity (lit. Mole -1. Cm-1) 2.48 * 105 Sandell’s sensitivity (µg. cm2/0.001 abs. unit) 0.09411 * 10-2 
Regression equation (y = mx + c) m-slope c- intercept y = 0.1047x + 0.004 0.1047 0.004 
Correlation co-efficient (r) 0.9984 Standard deviation 0.1465 RSD 0.4592 % range of error 
0.05 level 
0.01 level  0.0122 0.1812 LOD (limit of detection) 4.61 
LOQ (limit of quantification) 13.99 
 
CONCLUSION The developed UV-spectrophotometric method for determination of riluzole was found to be simple, accurate, precise, and economical. The method was proved to be robust and can be used for routine analysis of riluzole in bulk and in formulations. 
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